CH648754A5 - Pharmaceutical slow release tablet - Google Patents
Pharmaceutical slow release tablet Download PDFInfo
- Publication number
- CH648754A5 CH648754A5 CH7514/79A CH751479A CH648754A5 CH 648754 A5 CH648754 A5 CH 648754A5 CH 7514/79 A CH7514/79 A CH 7514/79A CH 751479 A CH751479 A CH 751479A CH 648754 A5 CH648754 A5 CH 648754A5
- Authority
- CH
- Switzerland
- Prior art keywords
- grooves
- tablets
- tablet
- cellulose
- release tablet
- Prior art date
Links
- 239000013543 active substance Substances 0.000 claims abstract description 9
- 239000011159 matrix material Substances 0.000 claims abstract description 7
- 230000000694 effects Effects 0.000 claims abstract description 5
- 239000003826 tablet Substances 0.000 claims description 49
- 239000000203 mixture Substances 0.000 claims description 16
- 239000004480 active ingredient Substances 0.000 claims description 13
- 229920001577 copolymer Polymers 0.000 claims description 10
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 10
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 10
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 10
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 10
- 230000000979 retarding effect Effects 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 8
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 8
- 230000002035 prolonged effect Effects 0.000 claims description 8
- 239000007939 sustained release tablet Substances 0.000 claims description 8
- 229920002678 cellulose Polymers 0.000 claims description 7
- 239000001913 cellulose Substances 0.000 claims description 7
- 235000010980 cellulose Nutrition 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 239000000454 talc Substances 0.000 claims description 5
- 229910052623 talc Inorganic materials 0.000 claims description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 4
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 150000002734 metacrylic acid derivatives Chemical class 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 4
- 239000011118 polyvinyl acetate Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 150000003626 triacylglycerols Chemical class 0.000 claims description 4
- 239000001993 wax Substances 0.000 claims description 4
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 230000000968 intestinal effect Effects 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 3
- 229920003023 plastic Polymers 0.000 claims description 3
- 239000004033 plastic Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 241000416162 Astragalus gummifer Species 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- 229920000715 Mucilage Polymers 0.000 claims description 2
- -1 Polyethylene Polymers 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 229920001615 Tragacanth Polymers 0.000 claims description 2
- 229920002433 Vinyl chloride-vinyl acetate copolymer Polymers 0.000 claims description 2
- SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 claims description 2
- 229940081735 acetylcellulose Drugs 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- 125000000129 anionic group Chemical group 0.000 claims description 2
- 235000013871 bee wax Nutrition 0.000 claims description 2
- 239000012166 beeswax Substances 0.000 claims description 2
- 239000000440 bentonite Substances 0.000 claims description 2
- 229910000278 bentonite Inorganic materials 0.000 claims description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 2
- 230000002146 bilateral effect Effects 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 239000004203 carnauba wax Substances 0.000 claims description 2
- 235000013869 carnauba wax Nutrition 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 239000012876 carrier material Substances 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 229920002301 cellulose acetate Polymers 0.000 claims description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 2
- 229960000541 cetyl alcohol Drugs 0.000 claims description 2
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 claims description 2
- 230000003111 delayed effect Effects 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 230000003628 erosive effect Effects 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 150000002191 fatty alcohols Chemical class 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 125000005456 glyceride group Chemical group 0.000 claims description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- 239000010514 hydrogenated cottonseed oil Substances 0.000 claims description 2
- 238000011068 loading method Methods 0.000 claims description 2
- 230000005923 long-lasting effect Effects 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims description 2
- 239000012188 paraffin wax Substances 0.000 claims description 2
- 239000004584 polyacrylic acid Substances 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 2
- 230000000750 progressive effect Effects 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 235000002639 sodium chloride Nutrition 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 229940012831 stearyl alcohol Drugs 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 2
- 235000010487 tragacanth Nutrition 0.000 claims description 2
- 239000000196 tragacanth Substances 0.000 claims description 2
- 229940116362 tragacanth Drugs 0.000 claims description 2
- LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 239000007916 tablet composition Substances 0.000 abstract 1
- 239000008187 granular material Substances 0.000 description 9
- 238000000576 coating method Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 229920001800 Shellac Polymers 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 229960002237 metoprolol Drugs 0.000 description 3
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 3
- 229960001300 metoprolol tartrate Drugs 0.000 description 3
- 235000013874 shellac Nutrition 0.000 description 3
- 239000004208 shellac Substances 0.000 description 3
- 229940113147 shellac Drugs 0.000 description 3
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- WUBVEMGCQRSBBT-UHFFFAOYSA-N tert-butyl 4-(trifluoromethylsulfonyloxy)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OS(=O)(=O)C(F)(F)F)=CC1 WUBVEMGCQRSBBT-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000007941 film coated tablet Substances 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229960001523 chlortalidone Drugs 0.000 description 1
- JIVPVXMEBJLZRO-UHFFFAOYSA-N chlorthalidone Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-UHFFFAOYSA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000007942 layered tablet Substances 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
Priority Applications (24)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH7514/79A CH648754A5 (en) | 1979-08-16 | 1979-08-16 | Pharmaceutical slow release tablet |
| US06/177,028 US4353887A (en) | 1979-08-16 | 1980-08-11 | Divisible tablet having controlled and delayed release of the active substance |
| BE0/201740A BE884760A (fr) | 1979-08-16 | 1980-08-13 | Comprime secable permettant une liberation controlee et retardee de la substance active |
| DE3030622A DE3030622C2 (de) | 1979-08-16 | 1980-08-13 | Teilbare Tablette mit Retardeffekt für die Abgabe von Metoprolol oder Oxprenolol |
| FR8017858A FR2462908A1 (fr) | 1979-08-16 | 1980-08-13 | Comprime secable permettant une liberation controlee et retardee de la substance active |
| FI802542A FI76691C (fi) | 1979-08-16 | 1980-08-13 | Delbar tablett med kontrollerad och foerdroejd aktivaemnesavgivning. |
| CA000358243A CA1158555A (en) | 1979-08-16 | 1980-08-14 | Divisible tablet having controlled and delayed release of the active substance |
| ES494274A ES8106231A1 (es) | 1979-08-16 | 1980-08-14 | Procedimiento para la obtencion de una tableta divisible concesion controlada y retardada de la sustancia activa |
| LU82718A LU82718A1 (de) | 1979-08-16 | 1980-08-14 | Teilbare tablette mit kontrollierter und verzoegerter wirkstoffabgabe |
| GR62678A GR69943B (show.php) | 1979-08-16 | 1980-08-14 | |
| NL8004616A NL8004616A (nl) | 1979-08-16 | 1980-08-14 | Deelbaar tablet met gecontroleerde en vertraagde afgifte van werkzame stof. |
| PT71706A PT71706B (en) | 1979-08-16 | 1980-08-14 | Divisible tablet having controlled and delayed release of the active substance |
| GB8026549A GB2057878B (en) | 1979-08-16 | 1980-08-14 | Controlled and delayed release divisible tablet |
| IT49501/80A IT1145285B (it) | 1979-08-16 | 1980-08-14 | Compressa divisibile con erogazione controllata e ritardata di sostanza attiva |
| IL60839A IL60839A (en) | 1979-08-16 | 1980-08-14 | Divisible tablet having controlled and delayed release of a pharmaceutically active substance |
| IE1727/80A IE50108B1 (en) | 1979-08-16 | 1980-08-15 | Divisible tablet having controlled and delayed release of the active substance |
| NZ194681A NZ194681A (en) | 1979-08-16 | 1980-08-15 | Divisible tablets having delayed and controlled release of active substance |
| SE8005759A SE445802B (sv) | 1979-08-16 | 1980-08-15 | Delbar tablett med kontrollerad och fordrojd avgivning av verksamt emne |
| DK354580A DK153772C (da) | 1979-08-16 | 1980-08-15 | Delbar tablet med retardvirkning |
| AU61481/80A AU531058B2 (en) | 1979-08-16 | 1980-08-15 | Delayed release divisible tablet |
| JP11186280A JPS5659708A (en) | 1979-08-16 | 1980-08-15 | Dividable medicine controlling and delaying active substance release |
| ZA00805015A ZA805015B (en) | 1979-08-16 | 1980-08-15 | Divisible tablet having controlled and delayed release of the active substance |
| NO802447A NO156274C (no) | 1979-08-16 | 1980-08-15 | Fremgangsmaate til fremstilling av en delbar tablett med kontrollert og forsinket avgivelse av virksomt stoff. |
| MY198/87A MY8700198A (en) | 1979-08-16 | 1987-12-30 | Divisible tablet having controlled and delayed release of the active substance |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH7514/79A CH648754A5 (en) | 1979-08-16 | 1979-08-16 | Pharmaceutical slow release tablet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH648754A5 true CH648754A5 (en) | 1985-04-15 |
Family
ID=4326338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH7514/79A CH648754A5 (en) | 1979-08-16 | 1979-08-16 | Pharmaceutical slow release tablet |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JPS5659708A (show.php) |
| BE (1) | BE884760A (show.php) |
| CH (1) | CH648754A5 (show.php) |
| ZA (1) | ZA805015B (show.php) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006038916A2 (en) | 2004-05-21 | 2006-04-13 | Accu-Break Technologies, Inc. | Scored pharmaceutical tablets comprising a plurality of segments |
| JP2009515955A (ja) * | 2005-11-18 | 2009-04-16 | エーシーシーユー−ブレイク テクノロジーズ，インク． | セグメント化した薬の剤形 |
| JP2009541341A (ja) * | 2006-06-19 | 2009-11-26 | エーシーシーユー−ブレイク テクノロジーズ，インク． | セグメント状の薬剤の剤形 |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT207980Z2 (it) * | 1986-02-24 | 1988-03-14 | Smithkline Beckman Corp | Pastiglia farmaceutica avente corpo discoidale con contrapposte facce bombate. |
| ES2127737T3 (es) * | 1991-09-10 | 1999-05-01 | Takeda Chemical Industries Ltd | Tableta divisible. |
| UA67802C2 (uk) * | 1998-10-23 | 2004-07-15 | Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. | Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції |
| GB0030340D0 (en) * | 2000-12-13 | 2001-01-24 | Sorex Ltd | Briquettes |
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| CN102014877B (zh) * | 2008-01-25 | 2017-06-06 | 格吕伦塔尔有限公司 | 药物剂型 |
| FR2928836B1 (fr) * | 2008-03-21 | 2011-08-26 | Servier Lab | Forme galenique secable permettant une liberation modifiee du principe actif |
| PL2273983T3 (pl) | 2008-05-09 | 2017-01-31 | Grünenthal GmbH | Sposób wytwarzania pośredniego preparatu proszkowego i końcowej stałej postaci dawkowania z zastosowaniem etapu zestalania rozpyłowego |
| CA2765971C (en) | 2009-07-22 | 2017-08-22 | Gruenenthal Gmbh | Hot-melt extruded controlled release dosage form |
| JP2012533585A (ja) | 2009-07-22 | 2012-12-27 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 酸化感受性オピオイドのための不正使用防止剤形 |
| NZ608865A (en) | 2010-09-02 | 2015-03-27 | Gruenenthal Chemie | Tamper resistant dosage form comprising an anionic polymer |
| CA2808219C (en) | 2010-09-02 | 2019-05-14 | Gruenenthal Gmbh | Tamper resistant dosage form comprising inorganic salt |
| PT2736497T (pt) | 2011-07-29 | 2017-11-30 | Gruenenthal Gmbh | Comprimido resistente a adulteração proporcionando libertação imediata de fármaco |
| MX348491B (es) | 2011-07-29 | 2017-06-15 | Gruenenthal Gmbh | Tableta a prueba de manipulacion que proporciona liberacion inmediata de fármaco. |
| BR112014019988A8 (pt) | 2012-02-28 | 2017-07-11 | Gruenenthal Gmbh | Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico |
| ES2692944T3 (es) | 2012-04-18 | 2018-12-05 | Grünenthal GmbH | Forma de dosificación farmacéutica resistente a la manipulación y resistente a la descarga rápida de la dosis |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| WO2013187395A1 (ja) * | 2012-06-12 | 2013-12-19 | 第一三共株式会社 | 容易な服用性と分割性を有する錠剤 |
| EP3003283A1 (en) | 2013-05-29 | 2016-04-13 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
| JP6445537B2 (ja) | 2013-05-29 | 2018-12-26 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形 |
| JP6449871B2 (ja) | 2013-07-12 | 2019-01-09 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | エチレン−酢酸ビニルポリマーを含有する改変防止剤形 |
| WO2015078891A1 (en) | 2013-11-26 | 2015-06-04 | Farmaceutici Formenti S.P.A. | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
| WO2015087561A1 (ja) * | 2013-12-09 | 2015-06-18 | 第一三共株式会社 | 容易な分割性を有する錠剤 |
| JP5719479B1 (ja) * | 2013-12-09 | 2015-05-20 | 第一三共株式会社 | 容易な分割性を有する錠剤 |
| WO2015173195A1 (en) | 2014-05-12 | 2015-11-19 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
| US9872835B2 (en) | 2014-05-26 | 2018-01-23 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
| EP3285745A1 (en) | 2015-04-24 | 2018-02-28 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
| US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
-
1979
- 1979-08-16 CH CH7514/79A patent/CH648754A5/de not_active IP Right Cessation
-
1980
- 1980-08-13 BE BE0/201740A patent/BE884760A/fr not_active IP Right Cessation
- 1980-08-15 JP JP11186280A patent/JPS5659708A/ja active Granted
- 1980-08-15 ZA ZA00805015A patent/ZA805015B/xx unknown
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006038916A2 (en) | 2004-05-21 | 2006-04-13 | Accu-Break Technologies, Inc. | Scored pharmaceutical tablets comprising a plurality of segments |
| EP1755563A4 (en) * | 2004-05-21 | 2007-07-04 | Accu Break Technologies Inc | PHARMACEUTICAL TABLETS WITH TWO OR MORE UNIFORM SEGMENTS |
| EP1746979A4 (en) * | 2004-05-21 | 2007-07-04 | Accu Break Pharmaceuticals Inc | CARED PHARMACEUTICAL TABLETS WITH SEVERAL SEGMENTS |
| JP2008500400A (ja) * | 2004-05-21 | 2008-01-10 | アキュ−ブレイク テクノロジーズ インコーポレーテッド | ２個またはそれ以上の単位セグメントを含む医薬錠剤 |
| JP2008500401A (ja) * | 2004-05-21 | 2008-01-10 | アキュ−ブレイク テクノロジーズ インコーポレーテッド | 複数のセグメントを含む、刻み目のある医薬錠剤 |
| AU2005245025B2 (en) * | 2004-05-21 | 2010-06-03 | Accu-Break Technologies, Inc. | Pharmaceutical tablets comprising two or more unitary segments |
| US8158148B2 (en) | 2004-05-21 | 2012-04-17 | Accu-Break Technologies, Inc. | Pharmaceutical tablets comprising two or more unitary segments |
| JP2009515955A (ja) * | 2005-11-18 | 2009-04-16 | エーシーシーユー−ブレイク テクノロジーズ，インク． | セグメント化した薬の剤形 |
| US8231902B2 (en) | 2005-11-18 | 2012-07-31 | Accu-Break Technologies, Inc. | Segmented pharmaceutical dosage forms |
| JP2009541341A (ja) * | 2006-06-19 | 2009-11-26 | エーシーシーユー−ブレイク テクノロジーズ，インク． | セグメント状の薬剤の剤形 |
Also Published As
| Publication number | Publication date |
|---|---|
| BE884760A (fr) | 1981-02-13 |
| JPS5659708A (en) | 1981-05-23 |
| ZA805015B (en) | 1981-08-26 |
| JPS6361928B2 (show.php) | 1988-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH648754A5 (en) | Pharmaceutical slow release tablet | |
| DE3030622C2 (de) | Teilbare Tablette mit Retardeffekt für die Abgabe von Metoprolol oder Oxprenolol | |
| DE69428862T2 (de) | Linsenförmig pharmazeutische Tablette mit verzögerter Freigabe | |
| AT394310B (de) | Verfahren zur herstellung lagerstabiler, schnellzerfallender pharmazeutischer wirkstoff-presslinge | |
| DE69620606T2 (de) | Feste oral anzuwendende arzeneiform | |
| DE3586600T2 (de) | Dosierungsform eine vielzahl mit einer diffusionshuelle ueberzogener einheiten enthaltend. | |
| DE69420087T2 (de) | Pharmazeutische Tablette geeignet zur gestuften Freisetzung von Wirkstoffen | |
| DE3587274T2 (de) | Dosierungsform eine vielzahl mit einer diffusionshuelle ueberzogener einheiten enthaltend. | |
| DE69704712T2 (de) | Tablette mit gesteuerter freisetzung von alfuzosinhydrochlorid | |
| DE69729134T2 (de) | Pharmazeutische Tablette geeignet zur Wirkstofffreisetzung in aufeinanderfolgenden und vorherbestimmbaren Zeiträumen | |
| DE69003568T2 (de) | Arzneimittel mit verzögerter Freigabe. | |
| DE69326163T2 (de) | Verfahren zur herstellung von arzneiformen und kontrollierte freigabe und die soerhaltenen arzneiformen | |
| EP1166776B1 (de) | Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstofffreisetzung | |
| DE1258548C2 (de) | Verfahren zur Herstellung von Arzneimitteltabletten unter Verwendung von Kunstharzen als die Wirkstoffabgabe verzoegernde Einbettungsmassen | |
| DE1492107C3 (de) | Verfahren zur Herstellung einer Acetylsalicylsauretablette | |
| DE68908297T2 (de) | Formgepresste Zusammensetzungen. | |
| DE19940944A1 (de) | Retardierte, orale, pharmazeutische Darreichungsformen | |
| EP0052076B1 (de) | Schnellzerfallende Arzneimittel-Presslinge | |
| EP1110544A2 (de) | Verwendung eines Filmüberzuges als geschmacksmaskierendes Coating von oralen Darreichungsformen | |
| DD292837A5 (de) | Verfahren zur herstellung von cholestyramin-tabletten | |
| DE602006000819T2 (de) | Dipyridamol enthaltende Zusammensetzungen mit verlängerter Freisetzung und Verfahren zu deren Herstellung | |
| EP2679216B1 (de) | Arzneiform zur modifizierten Freisetzung von Betahistin | |
| EP2863891A1 (de) | Arzneiform zur verlängerten freisetzung von wirkstoffen | |
| EP0208144B1 (de) | Ambroxol oder bromhexin enthaltendes arzneimittelgranulat | |
| EP0218928B1 (de) | Pellets mit irregulärer Oberfläche, Verfahren zu deren Herstellung und Tabletten enthaltend diese Pellets |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PFA | Name/firm changed |
Owner name: CIBA-GEIGY AG TRANSFER- NOVARTIS AG |
|
| PL | Patent ceased |